SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating TAZ/autophagy axis

Fang Ma¹, Meng-Ge Ding¹, Yi-Yu Lei¹, Li-Hua Luo², Shun Jiang¹, Yu-Hua Feng¹ and Xian-Ling Liu¹

Abstract

Immune escape is an important mechanism in tumorigenesis. The aim of this study was to investigate roles of SKIL in tumorigenesis and immune escape of non-small-cell lung cancer (NSCLC). SKIL expression levels in NSCLC cell line, clinical sample, and adjacent normal tissue were measured by quantitative PCR, western blot, or immunohistochemistry. Lentivirus was used to overexpress/silence SKIL or TAZ expression. Malignant phenotypes of NSCLC cells were evaluated by colony formation, transwell, and MTT assays, and in xenograft mouse model. Syngeneic mice model and flow cytometry were used to evaluate T cell infiltration. Quantitative PCR and western blot were applied to evaluate relevant mRNA and protein levels, respectively. Co-immunoprecipitation was applied to unveil the interaction between SKIL and TAZ. SKIL expression was higher in NSCLC tissue compared to adjacent normal tissue. Silencing of SKIL inhibited malignant phenotypes of NSCLC cells and promoted T cell infiltration. SKIL-knockdown inhibited autophagy and activated the STING pathway in NSCLC cells through down-regulation of TAZ. Silencing of TAZ cancelled the effects of SKIL overexpression on malignant phenotypes and autophagy of NSCLC cells. Inhibition of autophagy reversed the effects of SKIL/TAZ overexpression on the STING pathway. In conclusion, SKIL promoted tumorigenesis and immune escape of NSCLC cells through upregulation of TAZ/autophagy axis and inhibition on downstream STING pathway.

Introduction

Non-small-cell lung cancer (NSCLC) remains a major global health threat, which affects 1.8 million people and causes an estimated 1.59 million death worldwide¹. Although currently there are several available treatments for NSCLC (e.g., surgery, radiotherapy, chemotherapy, and targeted therapy), the prognosis of NSCLC patients is still unsatisfactory². In the past few years, immunotherapy has emerged as a new treatment method for cancer. Immune system plays important roles in eliminating cancer cells before they can form clinically identifiable tumor. In order to survive this immune pressure, some of the cancer cells develop a way to escape the surveillance of immune system (so-called immune escape), mainly through interacting with immune checkpoint molecules expressed on regulatory T cells (e.g., cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1)) and subsequent inhibition of the activation of regulatory T cells³. Immunotherapy targeting those immune checkpoint molecules has been intensively studied and achieved success in clinical trials in NSCLC⁴.

Cyclic GMP–AMP (cGAMP) synthase (cGAS) and stimulator of interferon (IFN) gene (STING) were reported to play important roles in anti-cancer immunity, e.g., T cell immunity⁵–⁹. cGAS is a key cytosolic DNA sensor. When cytosolic DNA (e.g., microbial DNA) is detected, cGAS produces cGAMP which promotes the translocation of STING from endoplasmic reticulum and Golgi apparatus to perinuclear vesicles¹⁰,¹¹. Re-located STING could activate TANK-binding kinase 1 (TBK1), NF-κB, and interferon regulatory transcription factor 3 (IRF3), which then stimulate the production of IFN, an essential
factor in anti-cancer immunity, and other inflammatory cytokines. Previous studies reported that inhibiting DNA damage response proteins (poly-ADP-ribose polymerase (PARP) and checkpoint kinase 1 (CHK1)) could activate cGAS-STING-mediated anti-cancer immunity, and enhance the blockade of PD-1 checkpoint and infiltration of cytotoxic T cells. Those findings potentiate the cGAS–STING pathway as a therapeutic target to enhance the efficacy of PD-1 immune checkpoint inhibitors.

Firstly discovered as a proto-oncogene, SKIL (also known as SnoN) is a mediator of the transforming growth factor-β (TGF-β) signaling pathway and exerts oncogenic activity through inhibiting TGF-β/Smad pathway. Overexpression of SKIL was reported in esophageal squamous cell carcinoma (ESCC) and breast cancer, and amplification of SKIL was also found in NSCLC, prostate cancer, and head and neck squamous carcinoma (HNSC). In addition, SKIL was involved in reduction of proliferation of cancerous cells. Interestingly, a recent study reported that SKIL promoted the tumorigenesis of breast cancer by enhancing the activity of TAZ, which might be an important mechanism for the oncogenic effects of SKIL.

In our study, we investigated the relationship between SKIL and TAZ, and their functions on autophagy and malignant phenotype of NSCLC. We found that SKIL induced malignant phenotypes of NSCLC through upregulation of TAZ pathway and autophagy, which also led to inhibition on immune escape from T cell immunity through inhibition on the STING pathway.

### Methods

#### Sample collection and ethics

Human NSCLC and paired adjacent normal tissue samples were collected from patients who received surgery from 2017 to 2019 in Department of Oncology, The Second Xiangya Hospital, Central South University. After removal of tumor, blocks of tumor tissue (1 cm × 1 cm × 0.2 cm) and adjacent normal tissue were collected and put into formalin-fixed and paraffin-embedded (FFPE) blocks following standard procedure in pathology department, or frozen at −80°C for future analysis. Informed consent was obtained from each patient enrolled in our study. Our study protocol was approved by Institutional Ethics Committee of Central South University.

#### Cell culture

Human lung adenocarcinoma cell lines (HCC827, CALU-3, NCI-H1975), human lung carcinoma cell line (A549), human lung squamous cell carcinoma cell lines (NCI-H226, NCI-H520, SK-MES-1), human bronchial epithelial cell line (16HBE) which was immortalized from normal bronchial epithelial cells and retains their characteristic features, and anaplastic murine lung carcinoma cell line (Madison 109 lung carcinoma, M109) were obtained from Fenghui Biology (Hunan, China). All the cell lines have passed the STR authentication. After thawing, cell lines were cultured in RPMI-1640 culture medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were kept in humid atmosphere with 5% carbon dioxide at 37°C. Culture medium was changed every other day and cells were subcultured when reached 80% confluence. All the cultured cells were routinely checked for mycoplasma contamination.

#### Animal model

To evaluate the in vivo tumorigenesis of cell lines, BALB/c-nu nude mice were obtained from Department of Laboratory Animals, Central South University, divided randomly into two groups, injected subcutaneously with 0.5 × 10⁶ of tumor cells each. Size of tumor was monitored every 4 days using a caliper. Tumor volume was calculated by (tumor length × tumor width²)/2. On day 24, mice...
were euthanized by carbon dioxide and tumor blocks were collected from the animals for subsequent analysis. For syngeneic mice model, mouse lung cancer cell line (M109) and BALB/c mice were used instead, and 0.5 × 10^6 of cultured M109 cells were injected subcutaneously into each BALB/c mouse with Matrigel (1:1; BD Biosciences, USA). On day 21, mice were euthanized by carbon dioxide and tumor blocks were collected. All procedures were approved by Department of laboratory animals, Central South University. The investigators were blinded to the group allocation during the experiment and when assessing the outcome.

**Flow cytometry**

The collected tumor blocks were firstly minced into pieces and single-cell suspension were obtained by passing the tumor mince through a cell strainer (Corning, USA). After fixation and permeabilization using BD Cytofix/Cytoperm kit (554714, BD Biosciences), cells were stained with anti-CD3 (100246, Biolegend), anti-CD4 (100526, Biolegend), anti-CD45 (101917, Biolegend), or anti-CD8 (100722, Biolegend) antibody following standard flow cytometry protocol. Results were then obtained using Fortessa platform (BD Biosciences) and analyzed using FlowJo software (BD Biosciences). CD3 and CD45 were used to analyze total T cells (both CD45 and CD3 positive). Cytotoxic T cells were further analyzed using CD4 and CD8 after gating of CD3^+ cells, while cells from inguinal lymph node were used as reference of gating.

**Western blot**

Tissue or cell samples were homogenized in 1× phosphate-buffered saline (PBS). Protein concentration of the samples was determined using Pierce Rapid Gold BCA Protein Assay Kit (Themo Fisher, USA). One microgram of protein from each sample was loaded onto SDS-PAGE gel. After separation of the proteins using electrophoresis and transferring onto nitrocellulose membranes, targeted proteins were probed with specific primary antibody: SNAIL1 (#3895, CST), SLUG (#9585, CST), E-cadherin (#14472, CST), vimentin (#3932, CST), GAPDH (#97166, CST), STING (#13647, CST), TBK1 (#3504, CST), p-TBK1 (#5483, CST), IRF3 (#4302, CST), p-IRF3 (#29047, CST), β-actin (#58169, CST), Beclin-1 (#3738, CST), p62 (#39749, CST), LC3-I (#4599, CST), LC3-II (#2775, CST), TAZ (#4883, CST), CTGF (#10095, CST), CYR61 (#39382, CST), LATS2 (#5888, CST), Sav (#13301, CST), or p-TAZ (#59971, CST). On the next day, membranes were washed in 1× PBS, and cultured with anti-mouse IgG (#7076, CST) or anti-rabbit IgG (#7074, CST) secondary antibody depending on the type of primary antibody for 2 h at room temperature. Results were then visualized using gel-imaging system (GS-800, Bio-Rad, USA), followed by densitometric analysis.

**Quantitative PCR**

Total RNA was extracted using TRIzol reagents (Invitrogen, USA) following the manufacturer’s instruction. Frozen tissue samples were thawed at room temperature. After thawing, 50–100 mg tissue sample was homogenized in 1 ml of TRIzol reagent. For cell samples, 1 × 10^6 cells were lysed in 1 ml TRIzol reagent. After adding 0.2 ml chloroform, sample homogenate was incubated for 2 min and centrifuged for 15 min at 12,000 × g, 4 °C. The upper aqueous phase was transferred into a new tube and mixed with equal volume of 70% ethanol. The samples were filtered into a spin cartridge by centrifugation and the flow-through was discarded. The RNAs were then eluted using RNase-free water. After determination of RNA concentration by measuring absorbance of diluted samples at 260 and 280 nm using a spectrophotometer (NanoDrop, Thermo Scientific, USA), 1 μg RNA from each sample was used for reverse transcription. Quantitative PCR (qPCR) was performed using SYBR Select Master Mix (Invitrogen, USA) on ABI 7500 system (ABI, USA) following a standard procedure. Specific primers were purchased from Sangon Biotech (Shanghai, China). Detailed sequences for each primer pair are: human CXCL10, sense GTGGCATTCAGAGGATTAC CTC, antisense TATGATGCTTGCAGATTGATT; hu man CCL5, sense CCAGCAGTGCCTTCGTGCCAC, anti sense CTCTGAGTGGCAACACCTT, human IFN-β, sense CATTACCTGGAAGCCAAGAG, antisense CAATT GTCCAGTCCAGAGG; mouse CXCL10, sense CCA AGGTGGAGATTGACC, antisense GCTTTCGACT; mouse CCL5, sense ATATGGCTCGGACA CCACCTC, antisense TCCCTCGAGTGACAAACACG; SOX2, sense CCACCACATACAGTCTTCTACT, anti sense TGGAGTGAGGAGGAGGTAC; SKIL, sense A CAGTTTATTTCCTGGTCCCT, antisense GCCAT GGTACCCGAAAC; CD44, sense CCAGAGGAC AGTGTGTGGGCG, antisense ACTGTCCCTGCGGCTT GGTT; OCT3/4, sense CTCGAAAGCAGAGGAT CACC, antisense AAAGGCGCAATGGTGTTGG; CD133, sense CACTACCAAGGACAGGCGCTTC, antisense CAA CGCCCTCTTGGTCTTCTTGG; NANOG, sense CTCC ACAACATCTGACACCC, antisense CGTCA CACATGCTATTCTTCG.

**Transfection**

For overexpression of SKIL and TAZ genes, full coding region of target gene (human SKIL, mouse SKIL, human TAZ, or mouse TAZ) was amplified and cloned into lentivirus vector pLVX-IRES-Neo. For knockdown of SKIL and TAZ genes, short hairpin RNA (shRNA) was purchased (Sangon Biotech, China) and cloned into pLVX-IRES-Neo. Empty pLVX-IRES-Neo vector was used as
control. The lentivirus vectors were then used for the transfection of target cells. The transfection was performed using Lipofectamine 2000 system (Thermo Fisher, USA) following the manufacturer’s instruction. Cells were seeded in a six-well plate with packaging medium at 70–80% confluence and allowed to incubate overnight at 37 °C in humidified atmosphere with 5% CO₂. On the next day, cells were transfected with lentivirus vectors and incubated at 37 °C in humidified atmosphere with 5% CO₂. Packaging medium was carefully replaced 6 h after the transfection. Forty-eight hours after the transfection, cells with stable transfection were used for subsequent treatment and analysis.

MTT assay

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to evaluate the viability of cells. Briefly, after suspension in culture medium, cultured cells were mixed with equal volume of 5 mg/ml MTT (M2128, Sigma, dissolved in 1× PBS) and incubated at 37 °C for 1 h. After removing medium, 200 μl DMSO was used to suspend MTT metabolic product. Mixture was incubated at 37 °C for 10 min, and optical density (OD) was measured at 490 nm.

Colony formation assay

Briefly, cultured cells were trypsinized and suspended in culture medium. Four thousand cells were then suspended in culture medium containing 0.4% low-melting-point agarose (Sigma, USA), which was overlaid on hardened 1.2% agarose bottom layer in 60 mm dishes. After cooling, the dishes were incubated at 37 °C in humidified atmosphere with 5% CO₂. Culture medium was changed every 3 days. On day 14, colonies were stained with 1% crystal violet, and number of colonies which were larger than 200 μm was counted under a light microscope (Leica Microsystems, USA) and recorded.

Transwell assay

Transwell assay was performed to evaluate the migration and invasion ability of cells. Transwell inserts suitable for 24-well plates (8.0 μm pores, Corning, USA) were used. For cell invasion ability analysis, the down side of the transwell membrane on the inserts was coated with Matrigel (Corning, USA, diluted in cold DMEM) at 4 °C, and incubated at 37 °C for 30 min to allow gelling. After reaching 50–60% confluence, culture cells were trypsinized and suspended in culture medium. Cell suspension was placed into upper chamber of the insert with Matrigel, and the insert was put into a sterile 24-well plate containing 500 μl culture medium in each well. For cell migration ability analysis, the re-suspended cells were placed in to upper chamber without Matrigel. After incubation for 24 h in humidified atmosphere with 5% CO₂, cells on the upper side of the insert membrane was completely removed using cotton swab. Inserts were fixed using 4% polyfluoroalkoxy and stained with 1% crystal violet. Invasion or migration ability of cells was evaluated by number of cells attached to the lower side of the insert. Quantification of the cells was performed by imaging of the insert membranes and subsequent analysis using ImageJ.

Co-immunoprecipitation

Immunoprecipitation was performed according to Zhu et al. Briefly, high-salt lysis buffer was prepared using 420 mM NaCl, 50 mM HEPES-KOH (pH 7.8), 5 mM EDTA, 0.1% NP-40, 3 mM dithiothreitol (Sigma-Aldrich, USA), 0.5 mM PMSF (Sigma-Aldrich, USA), and 10 μg/ml aprotinin (Sigma-Aldrich, USA). Cells were lysed in high-salt lysis buffer. Before the immunoprecipitation, cell lysates were cleared using protein A-Sepharose beads (Protein tech, IL, USA). Protein A-Sepharose beads coupled with anti-SKIL antibody (19218-1-AP, Protein tech, IL, USA) were then used to precipitate endogenous SKIL in cell lysates. Precipitated proteins were subject to further western blot analysis.

Immunofluorescence staining

Cells were firstly let grow on coverslips. Before staining, cells were fixed in 4% formaldehyde in 10% methanol for 20 min. After blocking with 10% goat serum, cells were cultured with diluted LC3B primary antibody (#12741, CST, USA) for 1 h, and then secondary goat anti-rabbit IgG antibody conjugated with Alexa Fluor 594 (#8889, CST, USA) for 1 h at room temperature. After washing with 1× PBS, cells were stained with ProLong Gold Antifade Mountant with DAPI (P36935, Thermo Fisher, USA). Result was quickly visualized under a fluorescence microscope (Leica Microsystems, USA) with excitation at 561 nm.

Immunohistochemistry

Tumor and normal tissue were fixed in formalin for 24 h, and then dehydrated and embedded in paraffin following standard pathology procedure in pathology department. The FFPE blocks were then sectioned at 4 μm and stored at 4 °C. On the day of staining, slides were deparaffinized in xylene followed by ethanol, and then hydrated in de-ionized water. For antigen-retrieval, slides were heated in Tris-EDTA buffer (pH 9.0) in a pressure cooker for 3 min at full pressure and allowed to cool down in running tap water for 10 min. After washing with 1× PBS, slides were stained with anti-SKIL primary antibody (1:50, ab78979, abcam, USA) for 1 h, and then
HRP-conjugated anti-rabbit secondary antibody (1:1000, ab6721, Abcam, USA). Staining result was visualized using 3,3’-diaminobenzidine (DAB, D8001, Sigma-Aldrich, USA) under a light microscope (Leica Microsystems, USA).

Statistical analysis
Statistical analysis was performed using GraphPad Prism 7.0. Data meet normal distribution. Variance was similar between the groups that are being statistically compared. Student’s t-test was used to compare between two groups, while one-way ANOVA were used for multiple group comparison. P < 0.05 was considered statistically significant.

Results

SKIL and TAZ expression levels are higher in NSCLC tissue
In all, we collected tumor and adjacent tissue samples from 32 NSCLC patients, of which 15 patients had lung adenocarcinoma (LUAD) and 17 had squamous carcinoma (LUSC). Measurement of SKIL expression using qPCR and IHC showed that SKIL expression was significantly higher in NSCLC tissue (Fig. 1a, f). Analysis using western blot showed increased SKIL protein expression in NSCLC tumor tissue compared to adjacent normal tissue, and a positive correlation was found between SKIL mRNA and protein expression levels in tumor (Fig. S1A, B). Further subgroup analysis showed that SKIL expression was significantly higher in LUSC and LUAD tissue compared to adjacent normal tissue (P < 0.05, see Fig. 1b, c). We also investigated SKIL expression of NSCLC samples using TCGA database, and obtained similar results in LUSC (Fig. 1e) but not in LUAD (Fig. 1d). Screening of SKIL expression levels in lung cancer cell lines showed that SKIL mRNA expression was elevated in some of LUAD cell lines (NCI-H1975 and CALU-3) and LUSC cell lines (NCI-H520 and NCI-H226), compared to normal lung cell line (16HBE), while SKIL level was not elevated in HCC827, A549, and SK-MES-1 cell lines (Fig. 1g). Western blot results showed that SKIL protein expression was elevated in HCC827, A549, NCI-H1975, CALU-3, NCI-H520, and NCI-H226 cell lines, compared to control. Correlation analysis also showed a positive correlation between SKIL mRNA and protein expression levels in human lung cancer cell lines (Fig. S1C, D). Measurement of TAZ expression using qPCR also revealed increased TAZ mRNA levels in NSCLC tumor tissue compared to adjacent normal tissue (Fig. 1h). Correlation analysis showed a positive correlation between the relative SKIL expression levels and TAZ expression levels in tumor tissue of NSCLC patients (Fig. 1i). Results of lung cancer cell lines showed significantly higher TAZ expression levels in NCI-H226, NCI-H520, SK-MES-1, NCI-H1975, and HCC827 compared to control (16HBE), which was not seen in CALU-3 and A549 cell lines (Fig. 1j). This trend was different from the observations in SKIL expression in lung cancer cell lines (Fig. 1g). Overall, those results indicate that SKIL and TAZ expression levels are elevated in NSCLC. Based on the screening results from cell lines, CALU-3 (LUAD) and NCI-H520 (LUSC) which showed high expression of SKIL were chosen for subsequent analysis.

Silencing on SKIL expression inhibited malignant phenotype and in vivo growth of CALU-3 and NCI-H520
In order to understand the relationship between SKIL and malignant phenotype of NSCLC, we silenced SKIL in CALU-3 and NCI-H520. Based on qPCR results, we selected shSKIL#4 for subsequent analysis, which showed the most significant knockdown on SKIL expression in both cell lines (Fig. 2a). In addition, complementation experiment using another shRNA (shSKIL#2) showed that SKIL overexpression could reverse the effects of shSKIL#2 on cell viability, migration, invasion, and epithelial–mesenchymal transition (EMT) of NCI-H520 cell line (Fig. S3).

After SKIL was silenced by the shRNA we chose (shSKIL#4) (see qPCR and western blot results in Fig. 2a and S1E), CALU-3 and NCI-H520 showed significantly decreased viability, colony formation (proliferation), invasion, and migration abilities (Fig. 2b–g). Measurement of EMT markers showed decreased expression of SNAIL1, SLUG, and vimentin, and increased expression of E-cadherin in SKIL-silenced CALU-3 and NCI-H520 (Fig. 2h, i), indicating inhibited EMT in those cells. Expression levels of cancer stem cell markers (CD44, CD133, SOX2, OCT3/4, and NANOG) were also decreased after silencing of SKIL in CALU-3 and NCI-H520 (Fig. 2j, k). Overall, silencing of SKIL resulted in inhibited malignant phenotypes (viability, proliferation, invasion, migration, EMT, and cancer stem cell viability) in CALU-3 and NCI-H520. Furthermore, we also conducted in vivo xenograft experiments, and results showed a reduced tumor growth in xenograft generated from SKIL-silenced CALU-3 cells (Fig. 2l).

Silencing on SKIL expression increased T cell infiltration and release of chemokines via activation on the STING pathway
In addition to malignant phenotypes, we further investigated the influence of SKIL on T cell-related immune escape of tumor cells. A mouse-derived lung cancer cell line (M109) was treated with shSKIL (or control shRNA) and used to generate tumor in immunocompetent BALB/c mice (synergic model). After 21 days, mice were euthanized and tumor blocks were collected. Flow cytometry showed increased number of total T cell (CD3⁺ CD45⁺) and cytotoxic T cell (CD3⁺ CD45⁺ CD8⁺) in the
Fig. 1 Expression of SKIL in NSCLC tissue. qPCR measurement showed that SKIL expression was significantly higher in a NSCLC tissue (n = 32), b lung adenocarcinoma (LUAD) (n = 15), and c lung squamous carcinoma (LUSC) (n = 17), compared to adjacent tissue. Analysis on TCGA samples showed that SKIL expression was higher in d LUSC samples but not in e LUAD samples, compared to adjacent tissue. f Immunohistochemistry results showed increased SKIL protein expression in NSCLC compared to adjacent normal tissue. g SKIL mRNA expression levels were elevated in NCI-H1975, CALU-3 (both are LUAD), NCI-H520, and NCI-H226 (both are LUSC) cell lines, but not in other lung cancer cell lines screened (HCC827, A549, and SK-MES-1), compared to control normal lung cell line (16HBE). h TAZ mRNA expression was higher in tumor tissue compared to adjacent normal tissue. i Positive correlation was found between the relative expression levels of SKIL and relative expression of TAZ in lung cancer tissue. j TAZ expression was significantly higher in NCI-H226, NCI-H520, SK-MES-1, NCI-H1975, and HCC827 lung cancer cell lines compared to control cell line (16HBE), which was not observed in CALU-3 and A549 cell lines. *P < 0.05, **P < 0.01, ***P < 0.001. Experiments were performed in triplicate.
Fig. 2 Silencing of SKIL inhibited malignant phenotype of NSCLC. a After silencing of SKIL in CALU-3 and NCI-H520 cell lines using shRNA, SKIL expression was significantly inhibited in all the four shRNAs (shSKIL#1–4) compared to control shRNA (shNC), while shSKIL#4 showed the lowest SKIL mRNA expression level. b, c MTT assay showed inhibited viability after SKIL was silenced (shSKIL) in CALU-3 and NCI-H520 compared to control (shNC). d, e Colony formation assay showed fewer colonies formed in CALU-3 and NCI-H520 with silenced SKIL expression (shSKIL) compared to control (shNC). f, g Transwell assay showed inhibited cell migration and invasion in the shSKIL group compared to the control group (shNC). h, i Western blot measurement showed decreased SNAIL1, SLUG, and vimentin expression levels, and increased E-cadherin levels in shSKIL group (shSKIL), compared to control group (shNC) in both CALU-3 and NCI-H520. j, k qPCR results showed that mRNA levels of cancer stem cell markers (CD44, CD133, Sox2, Oct3/4, and Nanog) were decreased after SKIL silencing (shSKIL) compared to control (shNC). l Tumorigenesis assay in nude mice using CALU-3 and NCI-H520 showed slower tumor growth rate and smaller size of collected tumor blocks after animal sacrifice in the shSKIL group (shSKIL) compared to the control group (shNC). *P < 0.05, **P < 0.01. Experiments were performed in triplicate.
SKIL-silenced xenograft model (Fig. 3a–d) compared to control. qPCR analysis showed that levels of chemokines (CXCL10, CCL5, and IFN-β) which are involved in cytotoxic T cell recruitment were elevated in SKIL-silenced CALU-3 and NCI-H520 at the presence of STING pathway agonist (cGAMP) and in SKIL-silenced xenograft model (Fig. 3e–h), indicating an activation of IFN-β pathway. Expression levels of STING were increased when SKIL was silenced, together with increased phosphorylation of STING downstream
signaling pathway factors, including TBK1 and transcription factor interferon regulatory factor 3 (IRF3) in CALU-3 and NCI-H520 at the presence of cGAMP and in SKIL-silenced xenograft model (Fig. 3i–j), indicating that knockdown of SKIL might influence T cell infiltration and release of relevant chemokines through activation of the STING pathway.

Silencing on SKIL expression inhibited autophagy and attenuated TAZ activation

Since SKIL was reported to regulate autophagy in several types of cancer, we also investigated the relationship between SKIL and autophagy in NSCLC. Measurement on autophagy-related markers (LC3-II/I, p62, and Beclin-1) showed decreased levels of those markers in SKIL-silenced CALU-3 and NCI-H520 (Fig. 4a). Formation of autophagosome was also inhibited in SKIL-silenced cell lines, indicated by decrease of cells with LC3-positive vacuoles (Fig. 4b, c). Previous study found that SKIL could promote tumorigenesis of breast cancer through enhancement of TAZ signaling. In addition, TAZ was reported to regulate autophagy in different types of cancer. Therefore, we also measured levels of TAZ and its downstream factors, and results showed decreased levels of TAZ and its downstream factors (CTGF, CYR61) in SKIL-silenced cell lines (Fig. 4d), suggesting that SKIL might regulate autophagy via regulation on the TAZ pathway in NSCLC.

We further investigated the possible interaction between SKIL and TAZ. Results showed that SKIL silencing accelerated TAZ degradation when treated with cycloheximide (Fig. 4e, f). Co-immunoprecipitation (co-IP) results showed that SKIL could bind to elements of hippo complex (LATS2 and Salvador, Sav), but not TAZ (Fig. 4g). Overexpression of LATS2, an inhibitor of TAZ, promoted degradation of TAZ through phosphorylation, while SKIL overexpression inhibited phosphorylation and degradation of TAZ without influencing the level of LATS2 (Fig. 4h). Those results suggest that SKIL could indirectly regulate TAZ activation through interaction with LATS2, which might be involved in the regulation of SKIL on autophagy in NSCLC.

TAZ is involved in the induction of autophagy and malignant phenotype of NSCLC cells by SKIL

To further demonstrate the role of TAZ in the relationship between SKIL and malignant phenotype and autophagy of NSCLC cell, we used vectors to overexpress SKIL in CALU-3 and NCI-H520 and then silenced TAZ expression in those cells (Fig. 5a). Overexpression of SKIL significantly increased cell viability, and invasion and migration abilities in CALU-3 and NCI-H520, while further silencing of TAZ led to decreased cell viability, and migration and invasion abilities compared to SKIL overexpression group (Fig. 5b–e), indicating that TAZ plays key roles in the regulation of malignant phenotype by SKIL. Furthermore, overexpression of SKIL increased expression of SLUG and vimentin, decreased E-cadherin expression, as well as increased levels of cancer stem cell markers (CD44, SOX2, OCT3/4) and autophagy markers (LC3, p62, Beclin-1), while further TAZ silencing reversed the effect of SKIL on those markers compared to SKIL overexpression group (Fig. 5f–i). All those results indicate key roles of TAZ in the regulation of NSCLC malignant phenotype and autophagy by SKIL.

TAZ is involved in the regulation of T cell infiltration and release of chemokines by SKIL

After silencing TAZ in M109 cell line, we transplanted those cells into BALB/c mice. Tumor blocks were collected after euthanizing mice using carbon dioxide on day 21. Flow cytometry showed increased numbers of total T cell and cytotoxic T cell (Fig. S4A–D) in tumor blocks generated by TAZ-silenced M109 cells. qPCR results showed that levels of chemokines (CXCL10, CCL5, IFN-β) were increased after silencing of TAZ in CALU-3, NCI-H520, and M109 at the presence of STING pathway agonist cGAMP and in SKIL-silenced NSCLC cell-derived tumor blocks (Fig. S4E–H). Subsequent analysis showed that levels of STING and phosphorylation of its pathway downstream factors (p-TBK1, p-IRF3) were elevated when TAZ was silenced (Fig. S4I, J). Those effects after TAZ silencing were similar to that of SKIL silencing (Fig. 3a, j), indicating that TAZ may be involved in the regulation of T cell infiltration and release of chemokines by SKIL through STING pathway.

In order to further convince the role of SKIL/TAZ axis in immune escape, we overexpressed SKIL in M109 cells. In those cells, we further silenced the expression of TAZ. Those cells were transplanted into BALB/c mice and tumor blocks were collected after 21 days. After examination of flow cytometry, compared to control, SKIL-overexpressed tumor showed lower numbers of total T cells and cytotoxic T cells. Further silencing of TAZ significantly increased the numbers of total and cytotoxic T cells in tumor blocks, compared to SKIL-overexpression group (Fig. 6a–d). In addition, levels of chemokines (CXCL10, CCL5, IFN-β) were lower in SKIL-overexpressed tumor compared to control, and further TAZ silencing significantly increased chemokine levels in those SKIL-overexpressed tumor (Fig. 6i). Analysis on the expression levels of STING pathway showed that SKIL overexpression decreased STING levels and phosphorylation of its downstream factors (p-TBK1, p-IRF3), compared to control. Further silencing of TAZ significantly increased the levels of STING, p-TBK1, and p-IRF3, compared to SKIL-overexpression group (Fig. 6f). Those findings further demonstrated the important roles
Fig. 4 SKIL induced autophagy through inhibition on TAZ phosphorylation by LATS2 and degradation. a Western blot analysis showed that SKIL silencing decreased expression levels of autophagy markers (LC3, p62, and Beclin-1). b, c Immunofluorescence staining indicated significant decrease of autophagosome after SKIL silencing in both CALU-3 and NCI-H520 cell lines. Percentage of cells with LC3 vacuoles were counted and calculated from 100 cells in 20 fields. d Western blot analysis showed that SKIL silencing decreased expression of TAZ and its downstream signaling factors (CTGF, Cyr61). e, f Cycloheximide treatment resulted in faster TAZ protein degradation in SKIL-silenced CALU-3 (shSKIL) compared to control (shNC). g Co-immunoprecipitation assay showed that SKIL could bind to elements of Hippo complex (LATS2, Sav), but not TAZ. h Western blot analysis showed that overexpression of LATS2 led to increased phosphorylation of TAZ (p-TAZ) and decreased levels of TAZ. Further overexpression of SKIL reversed the effect of LATS2 overexpression on levels of p-TAZ and TAZ, without influencing LATS2 level. *P < 0.05, **P < 0.01. Experiments were performed in triplicate.
Fig. 5 (See legend on next page.)
of SKIL/TAZ axis in immune escape through regulation on STING pathway.

**TAZ and autophagy are involved in the regulation of T cell infiltration and release of chemokines by SKIL**

Instead of silencing SKIL or TAZ, we also overexpressed the expression of those two factors and used an autophagy inhibitor, bafilomycin, to treat CALU-3 and NCI-H520. Using cGAMP to activate STING pathway, both SKIL and TAZ overexpression resulted in decreased STING levels, which could be canceled by inhibition on autophagy using bafilomycin (Fig. 7a). Similarly, overexpression of SKIL and TAZ inhibited STING pathway activation (decreased levels of p-TBK1, p-IRF3) and expression of chemokines (CXCL10, IFN-β), whereas inhibition on autophagy could cancel the inhibition (Fig. 7b–e). Those results suggest that autophagy was involved in the regulation on STING pathway and T cell activation by SKIL and TAZ.

**Discussion**

Our study found that SKIL expression was increased in NSCLC and was associated with its malignant phenotypes and immune escape from T cell immunity. Further investigation on the underlying mechanism indicated that the promotion of malignant phenotype was through upregulation of TAZ by interaction with Hippo complex factors (LATS2) and subsequent activation of autophagy. The enhanced autophagy also inhibited STING pathway and activation of T cells, leading to increased immune escape.

Findings of previous studies indicated complex roles of SKIL in tumorigenesis. Expression of SKIL was elevated in many types of cancer16–18,34, but was also found to be inhibited in some subtypes of esophageal, ovarian, pancreatic, and breast cancer22,23. Chromosome region 3q26, which contains SKIL gene, was found to be amplified in 31.2% of NSCLC18, and similarly, our results showed that SKIL expression was elevated in tumor samples of NSCLC patients (see Fig. 1). In addition, for the first time, we demonstrated that SKIL could induce malignant phenotype and immune escape in NSCLC (Figs. 2 and 3). Further investigation showed that those effects of SKIL were dependent on upregulation of TAZ expression by interaction between SKIL and Hippo complex elements, Lats2 and Sav (Figs. 4 and 5). This finding was consistent with previous findings that SKIL (SnoN) promoted TAZ signaling through antagonizing Hippo complex in breast cancer32. TAZ was found to be over-activated in most types of cancer and is important for tumorigenesis30. Through upregulation on downstream factors (amphiregulin, CTGF and CYR61), TAZ could induce many malignant phenotypes of cancer, e.g., cancer stem cell viability, EMT, increased migration and invasion abilities, and higher potential of metastasis30. On the other hand, YAP/TAZ was reported to induce autophagy, and this YAP/TAZ–autophagy axis was involved in contact inhibition between normal cells, which was normally activated in cancer cells31. Our study results showed that SKIL induced autophagy in NSCLC cell lines, and TAZ was essential in this induction (Fig. 5i). Together, those findings indicate that in addition to TAZ signaling pathway (CTGF, CYR61), SKIL may also induce malignant phenotype of NSCLC cells through TAZ–autophagy axis.

Autophagy is a highly conserved cellular mechanism to sequestrate and degrade damaged cytoplasmic structures, which plays key roles in management of cell stress and survival35. Defected autophagy is commonly observed in cancer, and is involved in many malignant phenotypes of tumor, including motility, invasion, cancer stem cell viability, EMT, metastasis, etc.35. Previous studies also found roles of autophagy in immune response (e.g. affecting release of cytokines, survival, and activation of lymphoid cells), and defects in autophagy could promote immune escape of developing tumors36. SOX2 was found to induce escape of HNSC cells from T cell immunity through autophagy-dependent inhibition on STING pathway37. Similarly, our results showed that SKIL induced immune escape of NSCLC cells from T cell immunity through autophagy-dependent inhibition on STING pathway (Fig. 7), and TAZ was involved in the activation of autophagy in this signaling pathway (Fig. S4). Considering the previous findings that TAZ could regulate expression of SOX2 (ref. 36) which could also contribute to the regulation of autophagy and STING pathway37, and p62 (another critical autophagy-related protein) could attenuate STING pathway39, the SKIL/TAZ-induced inhibition on STING pathway may be mediated by multiple signaling pathways. On the other hand, STING was
reported to induce autophagy, which is important in clearance of DNA and viruses in cytoplasm. The induction of autophagy by STING was thought to be a primordial function of cGAS pathway, but may also be considered as a feedback mechanism for the regulation of STING pathway by autophagy. More investigations are required to further clarify their relationship.

In summary, our study showed that SKIL expression was increased in NSCLC, and SKIL promoted malignant phenotypes of NSCLC cells via TAZ-dependent upregulation of autophagy. In addition, to the best of our knowledge, our study is the first to show roles of SKIL in immune escape of cancer cells, and to illustrate the underlying mechanisms which involved upregulation of autophagy.
TAZ and autophagy, and subsequent inhibition on STING pathway. Further studies are needed to clarify more details in roles of SKIL in tumorigenesis and underlying molecular mechanisms.

**Author contributions**

Guarantor of integrity of the entire study, study design, and manuscript review: X.-L.L.; study concepts, definition of intellectual content, and manuscript editing: F.M.; literature research and data acquisition: M.-G.D.; clinical studies and experimental studies: Y.-Y.L.; data analysis: L.-H.L.; statistical analysis: Y.-H.F.; manuscript preparation: S.J.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Ethics approval**

Our study protocol was approved by Institutional Ethics Committee of Central South University.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at https://doi.org/10.1038/s41419-020-03200-x.

Received: 8 April 2020 Revised: 13 October 2020 Accepted: 15 October 2020
Published online: 02 December 2020

References

1. Torre, L. A., Siegel, R. L., Ward, E. M. & Jemal, A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol. Biomark. Prev. 25, 16–27 (2016).
2. Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y. W. & Buchanan, P. Lung cancer: biology and treatment options. Biochim. Biophys. Acta 1856, 189–210 (2015).
3. Carbone, D. P., Gandara, D. R., Antonia, S. J., Zielinski, C. & Paz-Ares, L. Non-small-cell lung cancer: role of the immune system and potential for immunotherapy. J. Thorac. Oncol. 10, 974–984 (2015).
4. Reck, M. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. Immunotherapy 10, 93–105 (2018).
5. Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity. Immunity 41, 843–852 (2014).
6. Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830–842 (2014).
7. Siwick, K. E. et al. Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity. Cell Rep. 25, 3074–3085.e3075 (2018).
8. Kitajima, S. et al. Suppression of STING associated with LKB1 loss in KRAS-dependent lung cancer. Cancer Discov. 9, 34–45 (2019).
9. Konno, H. et al. Suppression of STING-signaling through epigenetic silencing and nonsense mutation impedes DNA damage mediated cytokine production. Oncogene 37, 2037–2051 (2018).
10. Kho, L. T. & Chen, L. Y. Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches. EMBO Rep. 19, 1.
11. Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788–792 (2009).
12. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).
13. Sen, T. et al. Targeted DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 9, 646–661 (2019).
14. Shen, J. et al. PARP triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 79, 311–319 (2019).
15. Deheuninck, J. & Luo, K. Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Res. 19, 47–57 (2009).
16. Akagi, I. et al. SnoN overexpression is predictive of poor survival in patients with esophageal squamous cell carcinoma. Ann. Surg. Oncol. 15, 2965–2975 (2008).
17. Zhang, F. et al. Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res. 63, 5005–5010 (2003).
18. Hagerstrand, D. et al. Systematic interrogation of 3q26 identifies TLOC1 and SKL as cancer drivers. Cancer Discov. 3, 1044–1057 (2013).
19. Raffoul, F., Camplia, C. & Nanjundan, M. SnoN/SKl, a TGFbeta signaling mediator: a participant in autophagy induced by arsenic trioxide. Autophagy 6, 955–957 (2010).
20. Smith, D. M. et al. Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SKiI expression in ovarian carcinoma cells. Cell Death Differ. 17, 1867–1881 (2010).
21. Lazaru, K. A. et al. BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma. Nat. Commun. 9, 3327 (2018).
22. Jahchan, N. S., Duyang, G. & Luo, K. Expression profiles of SnoN in normal and cancerous human tissues support its tumor suppressor role in human cancer. PLoS ONE 8, e52794 (2013).
23. Shinozuka, E. et al. SnoN/SKiI modulates proliferation through control of hsa-miR-720 transcription in esophageal cancer cells. Biochem. Biophys. Res. Commun. 430, 101–106 (2013).
24. Zancanato, F., Battilana, G., Cordononsi, M. & Piccolo, S. YAP/TAZ as therapeutic targets in cancer. Curr. Opin. Pharmacol. 29, 26–33 (2016).
25. Piccolo, S., Dupont, S. & Cordononsi, M. The biology of YAP/TAZ. hippo signaling and beyond. Physiol. Rev. 94, 1287–1312 (2014).
26. Zancanato, F., Cordononsi, M. & Piccolo, S. YAP/TAZ at the roots of cancer. Cancer Cell 29, 783–803 (2016).
27. Lamarr, J. M. et al. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis. J. Biol. Chem. 294, 2302–2317 (2019).
28. Zhao, B., Li, L., Tumaneng, K., Wang, C. Y. & Guan, K. L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 24, 72–85 (2010).
29. Zhao, B. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747–2761 (2007).
30. Moroishi, T., Hansen, C. G. & Guan, K. L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 15, 73–79 (2015).
31. Pawel, M. et al. Contact inhibition controls cell survival and proliferation via YAP/TAZ-autophagy axis. Nat. Commun. 9, 2961 (2018).
32. Zhu, Q. et al. SnoN antagonizes the Hippo kinase complex to promote TAZ signaling during breast carcinogenesis. Dev. Cell 37, 399–412 (2016).
33. Tanaka, Y. & Chen, Z. J. STING specifies IFI3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci. Signal. 5, ra20 (2012).
34. Liu, C., Zhang, H., Zang, X., Wang, C. & Kong, Y. The influence of SnoN gene silencing by siRNA on the cell proliferation and apoptosis of human pancreatic cancer cells. Diagn. Pathol. 10, 30 (2015).
35. Mowery, E. E., Sharp, M. N. & Macleod, K. F. Autophagy in cancer metastasis. Oncogene 36, 1619–1630 (2017).
36. Ma, Y., Galian, L., Zitvogel, L. & Kroemer, G. Autophagy and cellular immune responses. Immunity 39, 211–227 (2013).
37. Tan, Y. S. et al. Mitigating SOX2-potentiated Immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine. Clin. Cancer Res. 24, 4242–4255 (2018).
38. Xiao, H., Jiang, N., Zhou, B., Liu, Q. & Du, C. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma. Cancer Sci. 106, 151–159 (2015).
39. Prabakaran, T. et al. Attenuation of cGAS-STING signaling is mediated by a p62/SQSTM1-dependent autophagy pathway activated by TBK1. EMBO J. 37, 640 (2018).
40. Gu, X. et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature 567, 262–266 (2019).